Mark your calendars!

Upcoming AABP Conferences

2008
Charlotte, North Carolina • September 25-27

2009
Omaha, Nebraska • September 10-12

2010
Albuquerque, New Mexico • August 19-21

2011
St. Louis, Missouri • September 22-24

2012
Montreal, Quebec, Canada • September 20-22

American Association of Bovine Practitioners

Prudent Drug Usage Guidelines

The production of safe and wholesome animal products for human consumption is a primary goal of members of the AABP. In reaching that goal, the AABP is committed to the practice of preventive immune system management through the use of vaccines, parasiticides, stress reduction and proper nutritional management. The AABP recognizes that proper and timely management practices can reduce the incidence of disease and therefore reduce the need for antimicrobials; however, antimicrobials remain a necessary tool to manage infectious disease in beef and dairy herds. In order to reduce animal pain and suffering, to protect the economic livelihood of beef and dairy producers, to ensure the continued production of foods of animal origin, and to minimize the shedding of zoonotic bacteria into the environment and potentially the food chain, prudent use of antimicrobials is encouraged. Following are general guidelines for the prudent therapeutic use of antimicrobials in beef and dairy cattle.

1. The veterinarian's primary responsibility to the client is to help design management, immunization, housing and nutritional programs that will reduce the incidence of disease and the need for antimicrobials.

2. Antimicrobials should be used only within the confines of a valid veterinarian-client-patient relationship; this includes both dispensing and issuance of prescriptions.

3. Veterinarians should properly select and use antimicrobial drugs.
   a. Veterinarians should participate in continuing education programs that include therapeutics and emerging and/or development of antimicrobial resistance.
   b. The veterinarian should have strong clinical evidence of the identity of the pathogen causing the disease, based upon clinical signs, history, necropsy examination, laboratory data and past experience.
   c. The antimicrobial selected should be appropriate for the target organism and should be administered at a dosage and route that are likely to achieve effective levels in the target organ.
   d. Product choices and regimens should be based on available laboratory and package insert information, additional data in the literature, and consideration of the pharmacokinetics and pharmacodynamics of the drug.
   e. Antimicrobials should be used with specific clinical outcome(s) in mind, such as fever reduction, return of mastitic milk to normal, or to reduce shedding, contagion and recurrence of disease.
   f. Periodically monitor herd pathogen susceptibility and therapeutic response, especially for routine therapy such as dry cow intramammary antibiotics, to detect changes in microbial susceptibility and to evaluate antimicrobial selections.
   g. Use products that have the narrowest spectrum of activity and known efficacy *in vivo* against the pathogen causing the disease problem.
   h. Antimicrobials should be used at a dosage appropriate for the condition treated for as short a period of time as reasonable, i.e., therapy should be discontinued when it is apparent that the immune system can manage the disease, reduce pathogen shedding and minimize recurrence of clinical disease or development of the carrier state.
   i. Antimicrobials of lesser importance in human medicine should be used in preference to newer generation drugs that may be in the same class as drugs currently used in humans if this can be achieved while protecting the health and safety of the animals.
   j. Antimicrobials labeled for use for treating the condition diagnosed should be used whenever possible. The label, dose, route, frequency and duration should be followed whenever possible.
   k. Antimicrobials should be used extra-label only within the provisions contained within AMDUCA regulations.
   l. Compounding of antimicrobial formulations should be avoided.
   m. When appropriate, local therapy is preferred over systemic therapy.
   n. Treatment of chronic cases or those with a poor chance of recovery should be avoided. Chronic cases should be removed or isolated from the remainder of the herd.
   o. Combination antimicrobial therapy should be discouraged unless there is information to show an increase in efficacy or suppression of resistance development for the target organism.
   p. Prophylactic or metaphylactic use of antimicrobials should be based on a group, source or production unit evaluation rather than being utilized as standard practice.
   q. Drug integrity should be protected through proper handling, storage and observation of the expiration date.

4. Veterinarians should endeavor to ensure proper on-farm drug use.
   a. Prescription or dispensed drug quantities should be appropriate to the production-unit size and expected need so that stockpiling of antimicrobials on the farm is avoided.
   b. The veterinarian should train farm personnel who use antimicrobials on indications, dosages, withdrawal times, route of administration, injection site precautions, storage, handling, record keeping and accurate diagnosis of common diseases. The veterinarian should ensure that labels are accurate to instruct farm personnel on the correct use of antimicrobials.
   c. Veterinarians are encouraged to provide written guidelines to clients whenever possible to describe conditions and instructions for antimicrobial use on the farm or unit.

Presented by the Bacterial Resistance and Prudent Therapeutic Antimicrobial Use Committee. Board approved March 1999.

Notes

Notes

Notes

EXCEDE®

(Ceftiofur Crystalline Free Acid)

Sterile Suspension

For subcutaneous injection in the posterior aspect of the ear where it attaches to the head (base of the ear) in lactating dairy cattle. For subcutaneous injection in the middle third of the posterior aspect of the ear or in the posterior aspect of the ear where it attaches to the head (base of the ear) in beef and non-lactating dairy cattle.

CAUTION

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

INDICATIONS

EXCEDE Sterile Suspension is indicated for treatment of bovine respiratory disease (BRD, shipping fever, pneumonia) associated with *Mannheimia haemolytica*, *Pasteurella multocida*, and *Histophilus somni* in beef, non-lactating dairy, and lactating dairy cattle. EXCEDE Sterile Suspension is also indicated for the control of respiratory disease in beef and non-lactating dairy cattle which are at high risk of developing BRD associated with *M. haemolytica*, *P. multocida*, and *H. somni*.

CONTRAINDICATIONS

As with all drugs, the use of EXCEDE Sterile Suspension is contraindicated in animals previously found to be hypersensitive to the drug.

WARNINGS

FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE.
KEEP OUT OF REACH OF CHILDREN.

Penicillins and cephalosporins can cause allergic reactions in sensitized individuals. Topical exposures to such antimicrobials, including ceftiofur, may elicit mild to severe allergic reactions in some individuals. Repeated or prolonged exposure may lead to sensitization. Avoid direct contact of the product with the skin, eyes, mouth and clothing. Sensitization of the skin may be avoided by wearing latex gloves.

Persons with a known hypersensitivity to penicillin or cephalosporins should avoid exposure to this product.

In case of accidental eye exposure, flush with water for 15 minutes. In case of accidental skin exposure, wash with soap and water. Remove contaminated clothing. If allergic reaction occurs (e.g., skin rash, hives, difficult breathing), seek medical attention.

The material safety data sheet contains more detailed occupational safety information. To obtain a material safety data sheet (MSDS) please call 1-800-733-5500. To report any adverse event please call 1-800-366-5288.

Injection of EXCEDE Sterile Suspension into the arteries of the ear is likely to result in sudden death to the animal.

RESIDUE WARNINGS

- **Following label use as a single treatment, a 13-day pre-slaughter withdrawal period is required.**
- **Following label use as a single treatment, no milk discard period is required for this product.**
- **Use of dosages in excess of 6.6 mg CE/kg or administration by unapproved routes (subcutaneous injection in the neck or intramuscular injection) may cause violative residues.**
- **A withdrawal period has not been established for this product in pre-ruminating calves.**
- **Do not use in calves to be processed for veal.**

PRECAUTIONS

Following subcutaneous injection in the middle third of the posterior aspect of the ear, thickening and swelling (characterized by aseptic cellular infiltrate) of the ear may occur. As with other parenteral injections, localized post-injection bacterial infections may result in abscess formation. Attention to hygienic procedures can minimize their occurrence.

Following injections at the posterior aspect of the ear where it attaches to the head (base of the ear), areas of discoloration and signs of inflammation may persist at least 13 days post administration resulting in trim loss of edible tissue at slaughter. Injection of volumes greater than 20 mL, in the middle third of the ear, may result in open draining lesions in a small percentage of cattle.

The effects of ceftiofur on bovine reproductive performance, pregnancy, and lactation have not been determined.

ADVERSE EFFECTS

Administration of EXCEDE Sterile Suspension into the ear arteries is likely to result in sudden death in cattle. During the conduct of clinical studies, there was a low incidence of acute death (nine out of approximately 6000 animals). Three of these deaths were confirmed to be the result of inadvertent intra-arterial injection. No other adverse systemic effects were noted for either the antibiotic or formulation during any of the clinical and target animal safety studies.

STORAGE CONDITIONS

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP]. Shake well before using. Contents should be used within 12 weeks after the first dose is removed.

HOW SUPPLIED

EXCEDE Sterile Suspension is available in the following package size: 100 mL vial

U.S. Patent No. 5,721,359 and other patents pending.

NADA #141-209, Approved by FDA

Distributed by:

Pfizer

Pharmacia & Upjohn Company
Division of Pfizer Inc, NY, NY 10017

www.EXCEDE.com or call 1-866-387-2287

818 188 004
692432
4725-23-000

Notes

"Vista® Once in a single Sub-Q injection provides my clients with the most complete respiratory protection available. Bovi-Shield® plus One Shot® can't match that."

Layne Carlson, DVM
Mountainview Veterinary Service, PC
Twin Bridges, Montana



The Most Complete Protection, *Period.*

Settling for the *status quo* isn't the way you help your clients reach their goals. Vaccinating with anything but the best doesn't cut it. Demand the unequaled respiratory protection of Vista® Once SQ.

- **Sub-Q administration for better beef – Vista Once has it, Bovi-Shield® doesn't**
- **Avirulent live protection for both *Mannheimia haemolytica* and *Pasteurella multocida* – Vista Once has both, One Shot® doesn't**
- **Unequaled respiratory Duration of Immunity (DOI) for IBR, BVD Type 1 and BVD Type 2**
- **Persistent Infection (PI) protection against BVD Type 1 and BVD Type 2**
- **Offering the only Fetal Infection protection for BVD Type 1**
- **Single-dose BRSV protection**

Demand the most complete respiratory protection available, period. Switch your recommendation to Vista Once SQ today.

Vista®

SQ

intervet

RESEARCH • PERFORMANCE • INTEGRITY

P.O. Box 318
29160 Intervet Lane
Millsboro, Delaware 19966-0318
intervetusa.com · 800.441.8272



EXCEDE®. MORE THAN BETTER SCIENCE, IT'S BETTER MATH.

In a single dose, EXCEDE *(ceftiofur crystalline free acid)* Sterile Suspension delivers the kind of BRD therapy that used to require 3 to 5 doses.

- Powerful, sustained-release, broad-spectrum antibiotic performance
- Extended therapy in a single dose for greater compliance, fewer dosing errors
- Zero-day milk discard for 100% peace of mind
- All with simple, base of ear injection

Ask about EXCEDE. No matter how you add it up, it equals more disease treatment with less handling.

As with all drugs, the use of EXCEDE is contraindicated in animals previously found to be hypersensitive to the drug. Though safe in cattle when properly given, inadvertent intra-arterial injection in the ear is possible and is fatal. EXCEDE has a pre-slaughter withdrawal time of 13 days.

EXCEDE® (Ceftiofur Crystalline Free Acid) Sterile Suspension

Pfizer Animal Health

No other dose goes so far.™

www.excede.com 1-866-387-2287